Seidel W F, Cohen S, Bliwise N G, Dement W C
Center for Insomnia Research, Center Stanford University School of Medicine, Palo Alto, California.
Ann Allergy. 1987 Dec;59(6 Pt 2):58-62.
Sixty healthy men and women with no sleep complaints, 21 to 45 years of age (mean age 28), were randomly assigned to one of five parallel groups that received one of the following: cetirizine 5 mg (n = 13), 10 mg (n = 13), or 20 mg (n = 11); hydroxyzine 25 mg (n = 12); or placebo (n = 11). After one adaptation night in the lab, the subjects' sleep patterns were recorded from 2300 to 0730 hours. Subjects were in bed during this period. When they awoke at 0730, a test agent was administered according to double-blind technique. Multiple Sleep Latency Tests (MSLT: 20-minute opportunities to fall asleep in bed while EEG and eye movements are recorded) were given at two-hour intervals throughout the day, and a 30-minute vigilance performance test was given at 1000 and 1600 hours. Subjects receiving cetirizine in doses of 5 to 20 mg did not differ from placebo controls in any objective or subjective measure of daytime alertness. Subjects receiving hydroxyzine were significantly more sedated and showed slower reaction times than the placebo control group for at least four hours after treatment. Self-rated feelings of sleepiness, impairment, and fatigue did not differ significantly between groups. This suggests that hydroxyzine subjects may not have been aware of their sleepiness and slower reaction times.
60名年龄在21至45岁(平均年龄28岁)、无睡眠问题主诉的健康男女被随机分配到五个平行组之一,分别接受以下治疗之一:西替利嗪5毫克(n = 13)、10毫克(n = 13)或20毫克(n = 11);羟嗪25毫克(n = 12);或安慰剂(n = 11)。在实验室度过一个适应夜后,记录受试者在23:00至07:30的睡眠模式。在此期间,受试者需卧床。当他们在07:30醒来时,按照双盲技术给予测试药物。全天每隔两小时进行多次睡眠潜伏期测试(MSLT:在床上入睡20分钟的机会,同时记录脑电图和眼动情况),并在10:00和16:00进行30分钟的警觉性能测试。接受5至20毫克剂量西替利嗪的受试者在任何白天警觉性的客观或主观测量方面与安慰剂对照组均无差异。接受羟嗪治疗的受试者在治疗后至少四个小时内比安慰剂对照组明显更困倦,反应时间更慢。各组之间自我评定的困倦感、功能损害和疲劳感无显著差异。这表明接受羟嗪治疗的受试者可能并未意识到自己的困倦和反应时间变慢。